<DOC>
	<DOCNO>NCT02182258</DOCNO>
	<brief_summary>The primary objective trial ass safety tolerability BIBF 1120 administer intravenous ( iv ) infusion 1 , 3 , 10 , 20 mg , assess absolute bioavailability orally administer 100 mg BIBF 1120 soft gelatine capsule . A secondary objective exploration pharmacokinetic ( PK ) BIBF 1120 single iv dosing , include dose proportionality .</brief_summary>
	<brief_title>Safety Tolerability Study BIBF 1120 Intravenous Infusion Absolute Bioavailability BIBF 1120 Soft Gelatine Capsule Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Nintedanib</mesh_term>
	<criteria>Healthy male accord follow criterion : 1 . Based upon complete medical history , include physical examination , vital sign ( blood pressure , pulse rate ) , 12lead ECG , clinical laboratory test 2 . Age ≥18 year ≤50 year 3 . Body mass index ( BMI ) ≥18.5 ≤29.9 kg/m2 4 . Signed date write informed consent prior admission study , accordance GCP local legislation 1 . Any finding medical examination ( include blood pressure , pulse rate , ECG ) deviate normal clinical relevance 2 . History current gastrointestinal , hepatic ( include Gilbert 's syndrome history bilirubin increase ) renal , respiratory , cardiovascular , metabolic , immunological hormonal disorder 3 . History relevant orthostatic hypotension , faint spell , blackouts 4 . Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder 5 . Chronic relevant acute infection 6 . History allergy/hypersensitivity ( include drug allergy excipients ) deem relevant trial judge investigator 7 . History bleed disorder include prolonged habitual bleeding , haematologic disease cerebral bleeding ( e.g . car accident ) commotio cerebri 8 . Intake drug long halflife ( &gt; 24 h ) within 1 month prior administration trial 9 . Use drug might influence result trial within 14 day prior administration trial 10 . Participation another trial investigational drug within 2 month prior administration trial 11 . Smoker ( &gt; 10 cigarette 3 cigar 3 pipes/day ) inability refrain smoke study day 12 . Alcohol abuse ( &gt; 30 g/day ) 13 . Drug abuse 14 . Blood donation ( &gt; 150 mL within 4 week prior administration trial ) 15 . Excessive physical activity within 5 day prior administration trial 16 . Any laboratory value outside reference range clinical relevance 17 . Male subject refuse minimise risk female partner become pregnant first dose day 3 month completion study . Acceptable method contraception male volunteer include vasectomy less 3 month prior administration , barrier contraception , medically accept contraceptive method . Acceptable method contraception female partner male volunteer include intrauterine device , tubal ligation , hormonal contraceptive least 2 month diaphragm spermicide . 18 . Homozygous genotype status UGT1A1*28 , *60 ( Gilbert polymorphism )</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>